Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.34 |
| ▸ | HSPA2 | P54652 | 3/20 | 0.34 |
| ▸ | POLRMT | O00411 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | YES1 | P07947 | 1/20 | 0.31 |
| ▸ | LYN | P07948 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26329190 | 0.88 | POLRMT (0.34) | TMPRSS2POLRMT | |
| SCHEMBL24312537 | 0.87 | POLRMT (0.35) | TMPRSS2POLRMT | |
| SCHEMBL24313283 | 0.86 | POLRMT (0.34) | TMPRSS2POLRMT | |
| SCHEMBL26944551 | 0.85 | HPGD (0.44) | HPGDABCB1TMPRSS2HSPA2POLRMT | |
| SCHEMBL26320148 | 0.85 | POLRMT (0.34) | TMPRSS2POLRMT | |
| SCHEMBL26328644 | 0.85 | POLRMT (0.34) | TMPRSS2POLRMT | |
| SCHEMBL24312586 | 0.84 | HPGD (0.41) | HPGDABCB1TMPRSS2HSPA2POLRMT | |
| SCHEMBL26209957 | 0.84 | POLRMT (0.33) | TMPRSS2POLRMT | |
| SCHEMBL26327618 | 0.83 | POLRMT (0.32) | TMPRSS2POLRMT | |
| SCHEMBL26398190 | 0.83 | POLRMT (0.32) | TMPRSS2POLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814406-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814406-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, ACE | HPGD 2300/4885ABCB1 1290/4885TMPRSS2 141/4885 |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | HPGD 2300/4885ABCB1 1290/4885TMPRSS2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.